A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

607

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

July 15, 2027

Study Completion Date

April 10, 2029

Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
DRUG

Acalabrutinib

Dose formulation: Capsule or Tablet

DRUG

Venetoclax

Dose formulation: Tablet

DRUG

Obinutuzumab

Dose formulation: Injection

Trial Locations (38)

1097

Research Site, Budapest

2298

Research Site, Waratah

3168

Research Site, Clayton

3220

Research Site, Geelong

4032

Research Site, Debrecen

6009

Research Site, Nedlands

10065

Research Site, New York

11040

Research Site, New Hyde Park

14263

Research Site, Buffalo

14642

Research Site, Rochester

19104

Research Site, Philadelphia

22908

Research Site, Charlottesville

28204

Research Site, Charlotte

32256

Research Site, Jacksonville

34295

Research Site, Montpellier

37044

Research Site, Tours

37203

Research Site, Nashville

44195

Research Site, Cleveland

63110

Research Site, St Louis

80501

Research Site, Longmont

84112

Research Site, Salt Lake City

85710

Research Site, Tucson

97401

Research Site, Eugene

98104

Research Site, Seattle

98109

Research Site, Seattle

92093-0052

Research Site, La Jolla

02115

Research Site, Boston

500 05

Research Site, Hradec Králové

708 52

Research Site, Ostrava - Poruba

30460, CZ

Research Site, Pilsen

85-168

Research Site, Bydgoszcz

80-219

Research Site, Gdansk

40-519

Research Site, Katowice

30-727

Research Site, Krakow

93-513

Research Site, Lódz

20-090

Research Site, Lublin

08025

Research Site, Barcelona

07010

Research Site, Palma de Mallorca

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY